Abstracts tagged "Biomarkers"

Abstract Number: 0844 • ACR Convergence 2025
Machine Learning Model Incorporating Baseline and Early Follow-up Clinical Data Predicts 52-Week Cutaneous Outcomes in Systemic Sclerosis
Kimberly Lakin¹, John Spivack¹, Jessica Gordon¹, Dana Orange² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Rockefeller University, New York, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: As treatment options for diffuse cutaneous systemic sclerosis (dcSSc) expand, the need for data-driven, efficient approaches to therapeutic switching is becoming more urgent. Additionally,…
Abstract Number: 0531 • ACR Convergence 2025
Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
Anthony Marotta¹, Walter P. Maksymowych², Stephen Bleakley¹, Stephanie Wichuk³ and Norma Biln⁴, ¹Augurex Life Sciences Corp, Vancouver, BC, Canada, ²Department of Medicine, University of Alberta, ⁵⁶⁸ Heritage Building, Edmonton, AB, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Augurex Life Sciences, Vancouver, BC, Canada
Background/Purpose: Novel biomarkers for axSpA are urgently needed to enable earlier diagnosis and improve patient outcomes. An assay for quantifying 14-3-3η autoantibodies (AAbs) has been…
Abstract Number: 0303 • ACR Convergence 2025
A Predictive Model for Liver Enzyme Elevations Based on Creatine Kinase in Idiopathic Inflammatory Myopathies
Shiri Keret¹, Tanya Chandra², Nantakarn Pongtarakulpanit², Kaushik Sreerama Reddy², Jesse Wilkerson³, Siamak Moghadam-Kia⁴, Dana Ascherman⁵, Chester V. Oddis⁵ and Rohit Aggarwal⁶, ¹Bnai Zion Medical Center, Atlit, Israel, ²University of Pittsburgh Medical Center, Pittsburgh, ³DLH, Bethesda, MD, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by elevated muscle enzymes, including creatine kinase (CK), aldolase, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and lactate dehydrogenase…
Abstract Number: 0029 • ACR Convergence 2025
A Novel B Cell Subpopulation Characteristic of IgA Vasculitis Identified by Single-Cell RNA Sequencing
Joao Carlos Batista-Liz¹, María Sebastián Mora-Gil², Evan Troendle³, Oisin Cappa³, Maite Leonardo⁴, Ana Peñalba⁴, Luis mARTIN pENAGOS⁵, Ligia Gabrie-Rodriguez⁶, Rafael Gálvez Sánchez⁶, Jose Luis Callejas⁷, Belen Sevilla⁸, Diego de Argila⁹, Esther Vicente-Rabaneda⁹, Santos Castañeda¹⁰, David Simpson³, Ricardo Blanco¹¹, Verónica Pulito Cueto¹ and Raquel Lopez Mejias¹, ¹IDIVAL, Santander, Spain, ²Immunopathology Group, IDIVAL, Santander, Spain, ³Queens University, Wellcome-Wolfson Institute for Experimental Medicine, Belfast, United Kingdom, ⁴Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Immunopathology Group, IDIVAL and Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁶Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ⁷Department of Internal Medicine, Hospital San Cecilio, Granada, Spain, ⁸Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Universitario de la Princesa, Madrid, Spain, ¹⁰Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ¹¹Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: IgA vasculitis (IgAV) is a systemic small-vessel vasculitis characterized by immune complex deposition containing aberrantly glycosylated IgA1. While its clinical manifestations are well defined…
Abstract Number: 2675 • ACR Convergence 2025
RANTES and CXCL10 as Potential Tear-Based Biomarkers Associated with Ocular Damage in Pediatric Chronic Anterior Uveitis
Ilaria Maccora¹, Mariia Pavlenko², Mekibib Altaye³, Hermine Brunner⁴, Alexandra Duell⁴, Megan Quinlan-Waters⁵, Alyssa Sproles⁶, Sherry Thornton⁴, Grant Schulert⁴, Virginia Miraldi Utz⁴ and Sheila Angeles-Han⁶, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, CCHMC, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric chronic anterior uveitis (CAU) leads to sight-threatening complications in approximately 50% of affected children. Among complications, cataract and glaucoma are among the most…
Abstract Number: 2494 • ACR Convergence 2025
Abatacept Reduces CD319+ (SLAM-F7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis
Mikel Gurrea-Rubio¹, Kohei Maeda², Qi Wu³, Phillip L Campbell², Camila I Amarista², Alexander Stinson⁴, Ray Ohara⁵, Laura Cooney⁶, Michael Whitfield⁷, Pei-Suen Tsou⁸, Dinesh Khanna⁸ and David Fox⁹, ¹University of Michigan - Ann Arbor, Ann Arbor, MI, ²Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, ⁴University of Michigan, Department of Internal Medicine, Division of Rheumatology, Ann Arbor, MI, ⁵University of Michigan, Department of Internal Medicine, Division of Rheumatology, West Bloomfield, MI, ⁶Immune Tolerance Network, Ann Arbor, MI, ⁷Geisel School of Medicine, Lebanon, NH, ⁸University of Michigan, Ann Arbor, MI, ⁹University of Michigan, Dexter, MI
Background/Purpose: While the ASSET clinical trial (placebo-controlled blinded trial of abatacept) in patients with diffuse cutaneous systemic sclerosis (dcSSc) did not meet its primary endpoint…
Abstract Number: 2243 • ACR Convergence 2025
Differences In GDF-15 Levels In Rheumatoid Arthritis Patients With Remission Or Mild Disease Activity Are Associated With Fewer Depressive Symptoms: Clinical Data And Bioinformatic Analysis
Jessica Roldan Ortega¹, Mario Peña², Evelyn Aranda Cano³, Luz Viruel⁴, Itzel Palafox Sosa⁵, David Vera Bustamante⁶, Fausto Sanchez-Muñoz², Yaneli Juarez-Vicuña⁷ and Laura Aline Martinez-Martinez⁸, ¹INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Federal District, Mexico, ²Instituto Nacional de Cardiologia Ignacio Chavez, Mexico city, Mexico, ³Departament of rheumatology Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Federal District, Mexico, ⁴Universidad Autónoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, ⁵Escuela Superior de Medicina-Instituto Politècnico Nacional, ciudad de mexico, Federal District, Mexico, ⁶Benemérita Universidad Autónoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, ⁷Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ⁸Rheumatology Department at National Institute of Cardiology Ignacio Chávez, Mexico City, Federal District, Mexico
Background/Purpose: Depression is a common comorbidity in rheumatoid arthritis patients and has a significant effect on the disease course. [Brock J, et al. Nat Rev…
Abstract Number: 1951 • ACR Convergence 2025
Quantitative HRCT Analysis in Sjögren’s Disease-associated ILD: CALIPER-Derived Imaging Biomarkers for Prognostic Assessment
Gaetano La Rocca¹, Francesco Ferro², Vincenzo Uggenti³, Beatrice Dei⁴, Giovanni Fulvio⁴, Michele Moretti⁴, Marta Mosca⁵, Chiara Romei³ and Chiara Baldini⁵, ¹University of Pisa, Rheumatology Unit, Pisa, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³University of Pisa, ²nd Radiology Unit, Pisa, Italy, ⁴Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ⁵University of Pisa, Pisa, Pisa, Italy
Background/Purpose: Interstitial Lung Disease (ILD) is a frequent manifestation of Sjögren’s Disease (SjD), associated with significant morbidity and mortality. However, data on the prevalence of…
Abstract Number: 1773 • ACR Convergence 2025
Redefining disease activity assessment in IgG4-Related Disease: The role of classical and novel biomarkers
Marta López¹, rafeal Benito-Melero², Laura Martinez-Martinez³, Hye Sang-Park⁴, sara Calleja³, Helena Codes Mendez⁵, Mar Concepción Martín³, Berta Magallares³, Ivan Castellví⁶, Ana Laiz⁵, Cesar Diaz³ and Hector Corominas⁷, ¹Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ²MD, barcelona, Spain, ³Hospital Santa Creu i Sant Pau, Barcelona, Spain, ⁴Hospital Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁵Sant Pau Hospital, Barcelona, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, barcelona, Spain, ⁷Hospital de Sant Pau, Barcelona, Spain
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory disorder characterized by elevated serum IgG4 levels and tissue infiltration by IgG4-positive plasma cells. Despite advances in…
Abstract Number: 1619 • ACR Convergence 2025
Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
Gaston Ariel Ghio¹, Maria Gabriela Paz Machado², Evelin Encalada², Imma Perez Nadales², Georgina Salvador Alarcón², Elena Riera Alonso², manel pujol², Marta Pujol Teixidor² and Silvia Martinez Pardo², ¹Hospital Universitari Mùtua Terrassa, Terrassa, Catalonia, Spain, ²Hospital Universitari Mùtua Terrassa, Terrassa, Spain
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are chronic inflammatory disorders predominantly affecting patients over 50. Despite unclear etiopathogenesis, both conditions share central…
Abstract Number: 1367 • ACR Convergence 2025
Molecular Signature Response Classifier Identifies Contribution of GLP-1 Therapy to TNF Inhibitor Response in Rheumatoid Arthritis Patients
Lixia Zhang¹, Angus Wong², Alex Jones², Sherry Guardiano², Reginald Seeto² and Ryan T, Phan³, ¹Scipher Medicine, Plainsboro, NJ, ²Scipher Medicine, Waltham, ³Scipher Medicine, Los Gatos
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are extensively utilized in the management of rheumatoid arthritis (RA). Therapeutic responses remain highly heterogeneous. Emerging evidence suggests glucagon-like…
Abstract Number: 1168 • ACR Convergence 2025
Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory
Karis Lee¹, Min Kyung Lee² and Stanley Naides³, ¹Labcorp, Orlando, FL, ²Labcorp, Durham, NC, ³Labcorp, Dana Point, CA

Background/Purpose: Interstitial lung disease (ILD) is frequent in systemic autoimmune rheumatic diseases (SARDs) and is associated with poor prognosis. The prevalence of ILD is approximately…
Abstract Number: 0629 • ACR Convergence 2025
Characterizing Arthritis Subtypes in SLE: Prevalence, Clinical Features, and the Role of Type I Interferon Signatures
Pankti Mehta¹, Fadi Kharouf², Virginia Carrizo Abarza³, Qixuan Li⁴, Dafna D. Gladman⁵, Zahi Touma⁶ and Laura Whitall Garcia⁷, ¹University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: We aimed to study the prevalence of subtypes of lupus arthritis and determine their association with clinical features, serology, and type I interferon signature.Methods:…
Abstract Number: 0842 • ACR Convergence 2025
Association of urinary biomarkers with histological features in diagnostic and per-protocol repeat kidney biopsies in lupus nephritis
Andrea Fava¹, CHEN-YU LEE¹, Carla Guthridge², Dionysis Nikolopoulos³, Julius Lindblom⁴, Farah Tamirou⁵, Michelle Petri⁶, Joel Guthridge², Frederic Houssiau⁷ and Ioannis Parodis⁸, ¹Johns Hopkins University, Baltimore, MD, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden, ⁵Cliniques universitaires Saint-Luc, Brussels, Belgium, ⁶Johns Hopkins University School of Medicine, Timonium, MD, ⁷CUSL, BRUSSELS, Belgium, ⁸Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden
Background/Purpose: Persistent intrarenal inflammation despite immunosuppression drives kidney damage and functional decline in lupus nephritis (LN). Yet, current guidelines do not recommend repeat biopsy to…
Abstract Number: 0516 • ACR Convergence 2025
Association between anti-cytosolic 5′-nucleotidase 1A (anti-cN1A) antibodies and lymphoma in primary Sjögren Disease (SD)
Pierre-Marie Duret¹, Maude Bouchard-Marmen², Loukas Chatzis³, Margherita Giannini⁴, François Severac⁵, FELTEN Renaud⁶, Dan Levy⁷, Benoit Nespola⁸, Emmanuel Chatelus⁹, Emmanuelle Dernis¹⁰, Valerie Devauchelle¹¹, Philippe Dieude¹², Jean-Jacques Dubost¹³, Anne-Laure Fauchais¹⁴, Bernard Geny¹⁵, Eric Hachulla¹⁶, Claire larroche¹⁷, Véronique Le Guern¹⁸, Jacques Morel¹⁹, Aleth Perdriger²⁰, Carine Salliot²¹, Alain SARAUX²², Damien Sène²³, Jean Sibilia²⁴, SORDET Christelle⁶, Olivier Vittecoq²⁵, Raphaele Seror²⁶, Gaetane Nocturne²⁷, Andreas Goules²⁸, Athanasios G. Tzioufas²⁹, Xavier Mariette³⁰, Jacques-eric GOTTENBERG³¹ and Alain Meyer³², ¹Colmar General Hospital; Strasbourg University Hospital, Strasbourg, France, ²CHU de Québec, Québec, QC, Canada, ³Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Greece, Athens, Greece, ⁴Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁵Département de Santé Publique, Groupe Méthodes en Recherche Clinique (GMRC), CHU de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁶Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁷Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁸Laboratoire d’Immunologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, Strasbourg, Alsace, France, ⁹Department of Rheumatology, University Hospital Strasbourg, France, Strasbourg, France, ¹⁰Service de Rhumatologie, Centre Hospitalier Le Mans, Le Mans, Le Mans, France, ¹¹UBO, Brest, France, ¹²Service de Rhumatologie, Hôpital Bichat APHP, Paris, Paris, Ile-de-France, France, ¹³Service de Rhumatologie, CHU Gabriel Montpied, Clermont-Ferrand, Clermont-Ferrand, France, ¹⁴UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, France, ¹⁵UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; FranceExplorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg;, Strasbourg, Alsace, France, ¹⁶Service de Médecine Interne et Immunologie Clinique, CHU de Lille, Hôpital Claude Huriez, Lille, Lille, France, ¹⁷Service de Médecine Interne, Hôpital Avicenne APHP, Bobigny, Paris, Ile-de-France, France, ¹⁸Cochin hospital, Paris, France, ¹⁹CHU and University of Montpellier, Montpellier, France, ²⁰Rennes University, Rennes, France, ²¹CHR orleans, Orleans, France, ²²CHU Brest, Brest, France, ²³Department of Internal Medicine, Lariboisière University Hospital, Université Paris Cité, Assistance Publique Hôpitaux de Paris, Paris, Ile-de-France, France, ²⁴Rheumatology Department, National Center for Rare autoimmune disease RESO,Strasbourg University Hospital, Strasbourg, Alsace, France, ²⁵Service de Rhumatologie & CIC-CRB ¹⁴⁰⁴, CHU de Rouen, Université de Rouen, Rouen, Rouen, France, ²⁶Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²⁷University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ²⁸Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Athens, Greece, ²⁹Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens Institute for Autoimmune Systemic and Neurologic Diseases, Athens, Athens, ³⁰Université Paris-Saclay, Le Kremlin Bicetre, France, ³¹Hautepierre Hospital, STRASBOURG, Alsace, France, ³²Service de Rhumatologie, Centre de référence des maladies auto-immunes rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, Explorations fonctionnelles musculaires, Service de physiologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, UR ³⁰⁷², Centre de Recherche en Biomédecine, Université de Strasbourg, Strasbourg; France, Strasbourg, Alsace, France
Background/Purpose: There is an unmet clinical need for identification of novel biomarkers of systemic complications and lymphoma in primary Sjögren disease (SD). Anti-cytosolic 5'-nucleotidase 1A…

« Previous Page
1
…
7
8
9
10
11
…
109
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].